AmerisourceBergen 2014 Annual Report Download - page 25

Download and view the complete annual report

Please find page 25 of the 2014 AmerisourceBergen annual report below. You can navigate through the pages in the report by either clicking on the pages listed below, or by using the keyword search tool below to find specific information within the annual report.

Page out of 28

  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12
  • 13
  • 14
  • 15
  • 16
  • 17
  • 18
  • 19
  • 20
  • 21
  • 22
  • 23
  • 24
  • 25
  • 26
  • 27
  • 28

Fiscal year ended September 30, 2014 2013 % Change
Revenue
Pharmaceutical Distribution $117,383,967 $86,063,531 36.4%
Other 2,449,149 2,087,968 17.3%
Intersegment eliminations (263,989) (192,332) 37.3%
Revenue $119,569,127 $87,959,167 35.9%
Operating Income
Pharmaceutical Distribution $ 1,405,992 $ 1,162,352 21.0%
Other 150,617 128,074 17.6%
Total segment operating income 1,556,609 1,290,426 20.6%
Gains on antitrust litigation settlements 24,436 22,883
LIFO expense (348,063) (277,001)
Acquisition related intangibles amortization (23,167) (24,387)
Warrant expense (422,739) (90,055)
Employee severance, litigation and other (8,192) (23,467)
Operating income $ 778,884 $ 898,399 -13.3%
Percentages of Revenue:
Pharmaceutical Distribution
Gross Profit 2.36% 2.64%
Operating Expenses 1.16% 1.29%
Operating Income 1.20% 1.35%
Other
Gross Profit 21.84% 23.43%
Operating Expenses 15.69% 17.29%
Operating Income 6.15% 6.13%
AmerisourceBergen Corporation (GAAP)
Gross Profit 2.49% 2.85%
Operating Expenses 1.84% 1.83%
Operating Income 0.65% 1.02%
AmerisourceBergen Corporation (Non-GAAP)
Gross Profit 2.76% 3.14%
Operating Expenses 1.46% 1.67%
Operating Income 1.30% 1.47%
(dollars in thousands)
(unaudited)
See notes to consolidated financial statements in the Company’s Annual Report on Form 10-K as filed with the SEC for the Fiscal Year Ended September 30, 2014.
Management considers GAAP financial measures as well as the presented Non-GAAP financial measures in its evaluation of the Company’s operating performance.
Therefore, the Company believes that its presentation of Non-GAAP financial measures provides useful supplementary information to, and facilitates additional
analysis by, investors. 23
Summary Segment Information